Lisata Therapeutics’ (LSTA) “Buy” Rating Reiterated at HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 455.56% from the stock’s current price.

Lisata Therapeutics Price Performance

Shares of LSTA stock traded down $0.13 on Thursday, hitting $2.70. 3,910 shares of the stock traded hands, compared to its average volume of 12,983. The company has a market capitalization of $22.44 million, a PE ratio of -1.05 and a beta of 1.04. The company’s fifty day moving average is $3.03 and its 200 day moving average is $2.71. Lisata Therapeutics has a 1-year low of $1.95 and a 1-year high of $4.53.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.20. As a group, equities research analysts expect that Lisata Therapeutics will post -3.08 EPS for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC grew its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 5.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 284,669 shares of the company’s stock after acquiring an additional 14,830 shares during the quarter. Lisata Therapeutics accounts for 0.6% of BML Capital Management LLC’s holdings, making the stock its 23rd biggest position. BML Capital Management LLC owned 3.43% of Lisata Therapeutics worth $888,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.